News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News Novartis/Amgen migraine jab works in tough-to-treat patients Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.
News Sosei see Teva pipeline cull as an opportunity Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News Lilly chases Amgen with migraine drug filing Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
